{
    "clinical_study": {
        "@rank": "63748", 
        "arm_group": {
            "arm_group_label": "Open label active", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "The main purpose of this trial is to demonstrate the predictive value of the clinical\n      diagnosis of clearance of Actinic Keratoses after treatment with Ingenol Mebutate using\n      histopathological examination as the standard."
        }, 
        "brief_title": "Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Actinic Keratosis", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must be male or female and at least 18 years of age.\n\n          -  Female patients must be on non-childbearing potential or if of childbearing\n             potential then negative serum and urine pregnancy test and using effective\n             contraception\n\n          -  Ability to provide informed consent\n\n          -  Subjects must have 5-9 clinically typical, visible and discrete AK lesions within a\n             contiguous 25cm2 treatment area on the trunk and extremities except the back of the\n             hand\n\n          -  AK should be confirmed by histopathology of one of the AK's prior to inclusion\n\n        Exclusion Criteria:\n\n          -  location of the selected treatment area within 5cm of an incompletely healed wound or\n             within 10cm of a suspected basal cell carcinoma or squamous cell carcinoma\n\n          -  undergone Cosmetic or therapeutic procedures\n\n          -  use of acid-containing therapeutic products within 2cm of the selected treatment area\n             in the 2 weeks prior to Visit 1\n\n          -  use of topical creams/lotions, artificial tanners or topical steroids within 2cm of\n             the selected treatment areas in the 2 weeks prior to visit 1.\n\n          -  treatment with immunomodulators, or interferon/interferon inducers or systemic\n             medications that suppress the immune system within 4 weeks of visit 1\n\n          -  treatment with 5-FU, imiquimod, diclofenac, ingenol mebutate of photodynamic therapy\n             within 2cm of the treatment area in the 8 weeks prior to visit 1\n\n          -  use of systemic retinoids\n\n          -  those who are currently participating in any other interventional clinical trial\n\n          -  females who are pregnant or are breastfeeding\n\n          -  those known or suspected of not being able to comply with the requirements of the\n             protocol or provide consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892137", 
            "org_study_id": "LP0041-62"
        }, 
        "intervention": {
            "arm_group_label": "Open label active", 
            "description": "Once daily for 2 consecutive days", 
            "intervention_name": "Ingenol mebutate gel 0.05%", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Actinic Keratosis", 
            "Histopathology", 
            "Reflectance Confocal Microscopy", 
            "Local Skin Reaction"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "link": [
            {
                "description": "LEO Pharma", 
                "url": "http://www.leopharma.com"
            }, 
            {
                "description": "Therapeutic Goods Administration", 
                "url": "http://www.tga.gov.au"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kogarah", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2217"
                    }, 
                    "name": "Southderm Pty Ltd"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "north Sydney", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2060"
                    }, 
                    "name": "Melanoma Institute Australia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Benowa", 
                        "country": "Australia", 
                        "state": "Queensland", 
                        "zip": "4217"
                    }, 
                    "name": "The Skin Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Carina Heights", 
                        "country": "Australia", 
                        "state": "Queensland", 
                        "zip": "4152"
                    }, 
                    "name": "South East Dermatology Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Subiaco", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6008"
                    }, 
                    "name": "St John of God Dermatology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Victoria Park", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6100"
                    }, 
                    "name": "Burswood Dermatology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Augsburg", 
                        "country": "Germany", 
                        "zip": "86179"
                    }, 
                    "name": "Klinik f\u00fcr Dermatologie & Allergologie Klinikum Augsburg S\u00fcd"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }, 
                    "name": "Collegium Medicum Berlin GmbH"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany", 
                        "zip": "42275"
                    }, 
                    "name": "Medizinisches Zentrum Bonn Friedensplatz"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stuttgart", 
                        "country": "Germany", 
                        "zip": "70499"
                    }, 
                    "name": "Hautarztpraxis Prof. Dr. med. C. Termeer"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Germany"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%", 
        "overall_official": {
            "affiliation": "Collegium Medicum Berlin GmbH, Germany", 
            "last_name": "Martina Ulrich", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Australia: Human Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary response criterion is the clinical and histological clearance of AK at Day 57. Clinical Clearance will be measured by counting AKs, and histological clearance will be by performing a biopsy (result reported as AK or not AK).", 
            "measure": "Clearance of AK", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892137"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Efficacy in terms of complete clearance of AKs in the STA and histological clearance of pre-identified lesion.  AK clearance will be determined by AK count. Clearance of the pre-identified lesion will be assessed by a histopatholgist from a biopsy sample and reported as AK or not AK.", 
            "measure": "Complete clearance of AKs in the Selected Treatment Area", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}